Superiority of Low‐Dose Benzbromarone Add‐On to Low‐Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined‐Type Hyperuricemia
Primary result · SU target (<360 μmol/L) achievedResult — go to the resultOdds ratio 3.37 95% CI 1.90–5.98Authors' conclusion
Simply adding on low-dose benzbromarone (25 mg/day) to low-dose (20 mg/day) febuxostat showed superior urate lowering compared to febuxostat monotherapy in gout with a combined-type hyperuricemia.
Study context
- Population
- Patients with gout and combined-type hyperuricemia (renal urate underexcretion and overload) and eGFR >60 mL/min/1.73 m²219 completed 12 weeks
- Participants
- 250 patients
- Comparison
- Low-dose benzbromarone add-on to low-dose febuxostat vs febuxostat monotherapy
- Primary endpoint
- Proportion achieving serum urate (SU) <360 μmol/L
- Follow-up
- 12 weeks
Methodological detailsprospective, 1:1 randomisation, comparative effectiveness
- Prospective
- 1:1 randomisation
- Comparative effectiveness
Primary result
SU target (<360 μmol/L) achieved
Odds ratio
3.37
95% CI 1.90–5.98
By group
Febuxostat and benzbromarone combinationvs Febuxostat monotherapy
OR 3.37 (95% CI 1.90–5.98)
As reported in the abstract
Safety
Safety profiles
- Comparable between the two groups
Original publication
Superiority of Low‐Dose Benzbromarone Add‐On to Low‐Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined‐Type Hyperuricemia. Arthritis Care Res (Hoboken). Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →